Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss, but clinicians may prescribe it off-label. To buy it legally in the U.S., you need a prescription from a licensed provider and a licensed pharmacy. Options include your primary care clinician, telehealth, or Novo Nordisk’s NovoCare Pharmacy [1,2,3].
Quick facts about buying Ozempic for weight loss
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist; compounded semaglutide may also be prepared by licensed 503A pharmacies when legally appropriate, but compounded versions are not FDA-approved [1,11]. Ozempic’s FDA label is for type 2 diabetes and certain risk-reduction uses in people with type 2 diabetes, not chronic weight management [1].
- You cannot legally buy Ozempic in the U.S. without a prescription from a licensed clinician [3].
- Off-label prescribing is legal when a clinician decides it is medically appropriate, but it is not the same as FDA approval for that use [6].
- In the STEP 1 trial, semaglutide 2.4 mg once weekly was studied for chronic weight management in adults with overweight or obesity without diabetes; gastrointestinal side effects were common, and individual results vary [7].
- Only buy Ozempic through a licensed U.S. pharmacy. FDA has warned that counterfeit Ozempic has entered the U.S. drug supply [3].
Is Ozempic approved for weight loss?
No. Ozempic is FDA-approved for type 2 diabetes uses, not weight loss. Clinicians may prescribe it off-label, but that decision should include expected benefits, side effects, contraindications, cost, and FDA-approved alternatives [1,4,5,6].
What Ozempic is FDA-approved for
Ozempic is FDA-approved as an add-on to diet and exercise to improve blood sugar in adults with type 2 diabetes. Its label also includes certain cardiovascular, kidney, and mortality risk-reduction uses in adults with type 2 diabetes when label criteria are met [1].
The FDA-approved Ozempic label describes once-weekly subcutaneous dosing for diabetes care, including an initial 0.25 mg once weekly for 4 weeks before labeled escalation under clinician direction [1]. This is label information, not a dosing instruction for any reader.
Off-label use for weight loss
Using Ozempic for weight loss in a person without type 2 diabetes is off-label. Off-label prescribing is part of medical practice, but FDA has not approved Ozempic itself for chronic weight management [1,6].
Semaglutide has been studied for weight management. In the STEP 1 trial, adults with overweight or obesity who did not have diabetes received semaglutide 2.4 mg once weekly plus lifestyle support; the semaglutide group had greater average weight loss than placebo, but nausea, diarrhea, vomiting, and constipation were common, and some participants stopped treatment because of side effects [7]. Individual results vary.
How do you legally buy Ozempic in the U.S.?
To buy Ozempic legally in the U.S., you need a prescription from a licensed clinician and dispensing through a licensed pharmacy. Do not use websites that offer Ozempic without a prescription [3].
Getting a prescription from your doctor
A primary care clinician or endocrinologist may review your diagnosis, medicines, labs, weight history, pregnancy status, pancreatitis history, gallbladder history, kidney function, and thyroid cancer risk before prescribing Ozempic [1]. This matters because Ozempic has important warnings and contraindications [1].
If your goal is weight loss, say that clearly during the visit. Your clinician may discuss whether Ozempic is appropriate off-label, whether Wegovy or Zepbound better matches an FDA-approved weight-management indication, or whether another option is safer based on your history [1,4,5].
Buying Ozempic through telehealth
Telehealth can be a legal way to get evaluated for Ozempic if the clinician is licensed where you live and follows prescribing rules. A real telehealth visit should include medical screening, risk review, informed consent, and pharmacy dispensing through a licensed U.S. pharmacy [3].
NovoCare Pharmacy direct-to-patient
Novo Nordisk lists NovoCare Pharmacy as a direct-to-patient pharmacy option for certain Novo Nordisk medicines. NovoCare Pharmacy materials list some semaglutide-related cash-pay options at about $199 to $499 per month, depending on the product and program terms [2].
How much does Ozempic cost?
Ozempic cost depends on insurance, diagnosis, pharmacy, savings-card eligibility, and direct-to-patient options. Novo Nordisk’s Ozempic savings information states that eligible commercially insured patients may pay as little as $25 for up to a 3-month supply, subject to program limits [8].
| Payment path | What it may cost | What to know |
|---|---|---|
| Commercial insurance | Some eligible patients may pay as little as $25 for up to a 3-month supply with a manufacturer savings offer [8]. | Coverage is often tied to type 2 diabetes criteria. Many plans do not cover Ozempic for weight loss alone. |
| Cash-pay or self-pay | NovoCare Pharmacy materials list some semaglutide options around $199 to $499 per month, depending on product and program [2]. | Cash-pay pricing can change. Confirm the product, pharmacy, and total monthly cost before paying. |
| Traditional pharmacy list price | Manufacturer list-price materials have placed Ozempic near about $997 per monthly pen before discounts or insurance [8]. | List price is not always what a patient pays, but it explains why coverage and savings programs matter. |
| Medicare | Varies by plan and indication. | Medicare Part D generally excludes drugs used only for weight loss, but coverage may differ when a drug is used for another medically accepted indication [9]. |
| Medicaid | Varies by state. | State Medicaid programs set their own coverage rules within federal requirements. Prior authorization is common [9]. |
Cost with commercial insurance
Commercial plans often require documentation of type 2 diabetes before covering Ozempic. If Ozempic is prescribed off-label for weight loss, the plan may deny coverage even when the prescription itself is legal [1,6].
Cash-pay and self-pay pricing by dose
The FDA label describes Ozempic pens by labeled strengths and once-weekly administration, but patient cost is usually set by product, pharmacy, insurance contract, and savings program rather than only by dose [1,8]. Ask the pharmacy for the exact cash price before the prescription is filled.
Medicare and Medicaid coverage
Medicare Part D coverage for GLP-1 medicines depends on the drug and reason for use. Federal policy has generally excluded drugs used only for weight loss from Part D coverage, but a drug may be covered when used for another medically accepted indication [9].
Who is eligible to be prescribed Ozempic?
Ozempic eligibility starts with its FDA-labeled use: adults with type 2 diabetes who need improved blood sugar control as an add-on to diet and exercise [1]. A clinician must also review safety risks before prescribing [1].
Clinical criteria
For Ozempic, the clearest FDA-labeled group is adults with type 2 diabetes. The label also includes certain cardiovascular, kidney, and death-risk reduction uses for adults with type 2 diabetes when criteria are met [1].
For weight-loss medicines, FDA labels and clinical guidelines often use BMI criteria. Wegovy is indicated for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, along with reduced-calorie diet and increased physical activity [4]. Zepbound has an FDA-approved chronic weight-management indication for eligible adults, and both medicines have side effects and contraindications that require clinical review [5].
Can non-diabetics get Ozempic?
A person without diabetes can be prescribed Ozempic off-label only if a licensed clinician decides it is appropriate. That does not mean insurance will cover it, and it does not remove risks such as pancreatitis, gallbladder disease, kidney injury from dehydration, diabetic retinopathy concerns in people with diabetes, pregnancy concerns, and the thyroid C-cell tumor warning [1].
How is Ozempic dosed and taken?
Ozempic is a once-weekly injection under the skin, according to the FDA label [1]. Any dosing plan should come from the prescribing clinician, because side effects and safety risks can change how a medication is managed [1].
Starting dose and titration
The FDA-approved Ozempic label states that treatment for type 2 diabetes begins with 0.25 mg injected once weekly for 4 weeks before labeled escalation under clinician direction [1]. This is FDA-label information, not personal dosing advice.
Wegovy, which is semaglutide FDA-approved for chronic weight management, has a different FDA-labeled titration schedule that reaches 2.4 mg once weekly when tolerated [4]. Semaglutide products can cause nausea, vomiting, diarrhea, constipation, and abdominal pain, so any dose change should be managed by a clinician [1,4].
How to use the injection pen
Ozempic is given as a once-weekly injection under the skin of the abdomen, thigh, or upper arm according to the FDA label and Instructions for Use [1]. A pharmacist or clinician should show you how to store the pen, prepare the injection, choose an injection site, and dispose of sharps safely [1].
What are the side effects and risks?
Ozempic can cause side effects, and benefits should not be considered without risks. Common side effects in labeling include nausea, vomiting, diarrhea, abdominal pain, and constipation; these were also common in semaglutide weight-management research [1,7].
- Boxed warning: Ozempic has a boxed warning about thyroid C-cell tumors based on rodent findings and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1].
- Pancreatitis: the label warns about acute pancreatitis and advises discontinuation if pancreatitis is suspected [1].
- Gallbladder disease: semaglutide products have been associated with gallbladder problems, including cholelithiasis and cholecystitis [1,4].
- Kidney injury risk: severe vomiting or diarrhea can lead to dehydration, which may worsen kidney function in some people [1].
- Low blood sugar: risk is higher when Ozempic is used with insulin or insulin secretagogues such as sulfonylureas [1].
- Pregnancy: semaglutide products are generally not recommended during pregnancy; the Wegovy label advises stopping at least 2 months before a planned pregnancy because of the long half-life [4].
In the STEP 1 semaglutide weight-management trial, average weight loss was greater with semaglutide 2.4 mg than placebo, but gastrointestinal events were more frequent and some participants discontinued treatment due to side effects [7]. Individual results vary.
What if you can’t get or afford Ozempic? Alternatives to consider
If Ozempic is not covered, not available, or not the best fit, a clinician may compare FDA-approved weight-management medicines, diabetes medicines, and compounded options. The right choice depends on diagnosis, BMI, weight-related conditions, side-effect risk, contraindications, cost, and pharmacy access [1,4,5].
Wegovy (semaglutide for weight loss)
Wegovy is semaglutide, a GLP-1 receptor agonist, and is FDA-approved for chronic weight management in eligible adults and certain adolescents, along with reduced-calorie diet and increased physical activity [4]. In STEP 1, semaglutide 2.4 mg once weekly produced greater average weight loss than placebo, but nausea, diarrhea, vomiting, and constipation were common, and some participants stopped treatment because of side effects [7]. Individual results vary.
Mounjaro and Zepbound (tirzepatide)
Mounjaro is tirzepatide, a GIP and GLP-1 receptor agonist, FDA-approved for adults with type 2 diabetes [10]. Zepbound is tirzepatide with an FDA-approved chronic weight-management indication for eligible adults, and its label includes common side effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia [5].
Compounded semaglutide via 503A pharmacy
Compounded semaglutide is not FDA-approved, and compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before they are dispensed [11]. When legally appropriate, licensed 503A compounding pharmacies can prepare patient-specific prescriptions; Chia is one telehealth option that offers clinician-reviewed access to compounded GLP-1 medications through licensed U.S. pharmacy partners.
Oral semaglutide (Rybelsus)
Rybelsus is oral semaglutide, a GLP-1 receptor agonist tablet FDA-approved for adults with type 2 diabetes, not weight loss [12]. It may be an option for some people with type 2 diabetes who prefer an oral medicine, but it has its own administration rules, side effects, contraindications, and coverage limits [12].
3-min quiz
Compare GLP-1 options with a clinician
If you are weighing Ozempic, Wegovy, Zepbound, Rybelsus, or compounded semaglutide, a clinician can review your history, goals, coverage, and safety risks.
How do you avoid unsafe or counterfeit Ozempic online?
Ozempic should only come from a licensed pharmacy after a valid prescription. FDA has warned patients about counterfeit Ozempic in the U.S. drug supply and has warned against illegal online sellers that offer GLP-1 medicines without proper oversight [3].
- Avoid any site that sells Ozempic without a prescription [3].
- Avoid sellers that ship from unknown international sources or refuse to name the dispensing pharmacy.
- Check that the pharmacy is licensed in the state where it dispenses.
- Be cautious with prices that look far below normal market pricing.
- Do not use products labeled “research use only” or “not for human use.”
- Ask your pharmacist to verify the product if packaging, labeling, pen appearance, or lot information looks unusual.
Frequently asked questions
You can use online care to get evaluated, but you still need a valid prescription from a licensed clinician and dispensing through a licensed pharmacy. Ozempic is FDA-approved for type 2 diabetes, not weight loss, so weight-loss use is off-label [1,3].
Possibly, but only if a licensed clinician decides off-label prescribing is appropriate. Many insurance plans will not cover Ozempic for weight loss alone, and the same safety warnings still apply [1,6].
Both contain semaglutide, but they have different FDA labels. Ozempic is labeled for type 2 diabetes uses, while Wegovy is labeled for chronic weight management in eligible patients [1,4].
The lowest legal cost depends on your insurance, diagnosis, savings-card eligibility, and pharmacy. Eligible commercially insured patients may qualify for manufacturer savings, while cash-pay direct-to-patient options may have different published prices [2,8].
No. Compounded semaglutide is not FDA-approved and is not reviewed by FDA for safety, effectiveness, or quality before dispensing. It may be considered only through a licensed clinician and an appropriate licensed compounding pharmacy [11].
Yes. AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP (mcp.chia.health), but a licensed clinician must still review your medical history and decide whether any medication is appropriate.
Do not use it. Contact the pharmacy that dispensed it and ask for verification. FDA has warned about counterfeit Ozempic, and suspicious products can also be reported to FDA MedWatch [3].
No existing-articles list was provided for this draft. Internal link targets should be added by an editor before publishing so readers can move to related Chia resources.
3-min quiz
Talk with a licensed clinician
A clinical review can help you compare FDA-approved weight-loss medications, diabetes medications, and compounded options based on your health history and goals.
References
- 1.Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 2.Novo Nordisk. NovoCare Pharmacy direct-to-patient pharmacy information and cash-pay program materials, 2025.
- 3.U.S. Food and Drug Administration. FDA warns consumers not to purchase or use counterfeit Ozempic (semaglutide), 2023.
- 4.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 5.Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 6.U.S. Food and Drug Administration. Understanding unapproved use of approved drugs: off-label use, 2018.
- 7.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 8.Novo Nordisk. Ozempic savings and list price information, 2025.
- 9.Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements, 2024.
- 10.Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 11.U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss, 2025.
- 12.Novo Nordisk. Rybelsus (semaglutide) tablets prescribing information. U.S. Food and Drug Administration, 2024.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
